Press Release: New $50,000 Annual Prize for Outstanding Gynecologic Cancer Researcher Announced

The Claudia Cohen Research Foundation in association with the Gynecologic Cancer Foundation announces a new annual $50,000 Prize for Outstanding Gynecologic Cancer Researcher.

Claudia Cohen Research Foundation and GCF

This new prize of $50,000 is awarded to an individual in recognition of his or her outstanding contributions to research improving the care of women with gynecologic cancer.

The prize is funded by the Claudia Cohen Research Foundation (CCRF) in honor of Claudia Cohen who lost her battle with uterine leiomyosarcoma in 2007. Ms. Cohen was a highly respected journalist and philanthropist.

GCF is grateful to Ms. Cohen’s daughter Samantha, and her sisters Caleigh and Debra Perelman, for their funding of this award through the foundation they established to honor Ms. Cohen.

The first recipient is Dr. Paul Goodfellow. Over the past 20 years, Dr. Goodfellow has shared authorship on more than 150 published journal articles and abstracts, and has contributed to 15 reviews and book chapters and is an international leader in DNA mismatch repair research and endometrial cancer tumorgenesis.

He is the Director of the NCI-funded SPORE in Endometrial Cancer at the Alvin J. Siteman Cancer Center, University of Washington School of Medicine. There the Goodfellow Laboratory is currently investigating the genetic alterations that underlie the development of endometrial cancers, focusing on defective DNA mismatch repair and abnormalities in the MAPK signaling pathway.

The Claudia Cohen Foundation (hotlink) is dedicated exclusively to support research leading to the immunological treatment, control and prevention of gynecologic cancer with a special emphasis on gynecologic sarcoma.

For more information about the prize, and how apply or nominate a candidate for 2010-2011, contact Dina Zambon at

For media inquiries, contact Marsha Wilson at or mobile, 301.332.0117.


Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.


Vaccine efficacy against vulvar infection with HPV 16/18 was comparable to the efficacy found against cervical infection 4 years after vaccination, according to researchers with the National Cancer Institute.


The Foundation has published its 2014-2015 Research Grants and Awards Booklet with Applications. Please consider applying to become part of an elite group of physician-scientists committed to the well-being of women at risk for/affected by gyn malignancies.


The next Ovarian Cancer Survivors Course will be Saturday, July 26, 2014 in Boston. For more information on courses, click here.